



UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 20231
www.uspto.gov

APPLICATION NUMBER	FILING/RECEIPT DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
09/808,832	03/15/2001	Robert A. Copeland	PH-7134

CONFIRMATION NO. 5618

FORMALITIES LETTER



OC00000006056391

24348
Dupont Pharmaceuticals Company
Legal Department - Patents
1007 Market Street
Wilmington, DE 19898

Date Mailed: 05/09/2001

NOTICE TO FILE MISSING PARTS OF NONPROVISIONAL APPLICATION

FILED UNDER 37 CFR 1.53(b)

Filing Date Granted

An application number and filing date have been accorded to this application. The item(s) indicated below, however, are missing. Applicant is given **TWO MONTHS** from the date of this Notice within which to file all required items and pay any fees required below to avoid abandonment. Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 CFR 1.136(a).

- The oath or declaration is unsigned.
- To avoid abandonment, a late filing fee or oath or declaration surcharge as set forth in 37 CFR 1.16(e) of \$130 for a non-small entity, must be submitted with the missing items identified in this letter.
- **The balance due by applicant is \$ 130.**
- A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing." Applicant must provide a substitute computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d).


For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase PatentIn Software, call (703) 306-2600
- For PatentIn Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

07/03/2001 NYUSUF1 00000001 041920 09000032

01 FC:105 130.00 CH

A copy of this notice MUST be returned with the reply.

A handwritten signature in black ink, appearing to be "T. Hall", written over a horizontal line.

Customer Service Center

Initial Patent Examination Division (703) 308-1202

PART 2 - COPY TO BE RETURNED WITH RESPONSE



Attorney Dkt. No. PH-7134

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:	Copeland)	
U.S. Serial No.:	09/808,832)	Examiner: Not Yet Assigned
Filed:	03/15/01)	Art Unit: Not Yet Assigned
For:	Peptidase-Cleavable, Targeted Antineoplastic Drugs And Their Therapeutic Use)	

Hon. Commissioner of
Patents and Trademarks
Washington, D.C. 20231

RESPONSE TO NOTICE TO FILE MISSING PARTS

This communication is in response to the Notice to File Missing Parts mailed May 9, 2001. Applicants respectfully request reconsideration in view of the following remarks.

REMARKS

In response to the Notice to File Missing Parts the Applicants are submitting herewith a signed Declaration. Authorization is also given to charge a surcharge in the amount of \$130.00 for the late filing of the signed Declaration to Deposit Account 04-1928 (E.I. du Pont de Nemours and Company).

In addition, Applicants have been informed that while a copy of the Sequence Listing in computer readable form has been submitted, the content of the computer readable form does not comply with the requirements of 37 CFR 1.822 and/or 1.823 as indicated on the marked-up "Raw Sequence Listing."

A copy of a marked-up "Raw Sequence Listing" is enclosed here along with this response as required by the Notice to File Missing Parts. Also, Applicants are providing the U.S. Patent Office the following:


- (1) An substitute computer readable form (CRF) copy of the "Sequence Listing";
- (2) An substitute paper copy of the "Sequence Listing", as well as this amendment directing its entry into the specification (stated above); and
- (3) A statement that the content of the paper and computer readable copies are the same and includes no new matter, as required by 37 CFR 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d) (following below).

The Applicants direct the entry of the substitute CRF copy of the "Sequence Listing" along with a substitute paper copy of same into the specification. Applicants further state that the contents of the paper and CRF copies of the "Sequence Listing" are the same and include no new matter, as required by 37 CFR 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

Applicants maintain that the application is now in condition for substantive examination, and early notice to that effect is respectfully requested. No fee is deemed necessary in connection with this response's filing other than the \$130.00 surcharge required in connection with the late filing of the signed Declaration. However, if any other fee is deemed necessary, authorization is hereby given to charge the amount of such a fee to Deposit Account No. 04-1928.

6-26-01
(Date)

Respectfully submitted,


Kalim S. Fuzail
Attorney for Applicant
Registration No. 45,805
Telephone: 302-992-3215

PH-7134 Response (June 2001).doc



Certificate of Mailing under 37 CFR 1.8

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the Application of:

Robert A. Copeland et al

CASE NO.: PH-7134

APPLICATION NO.: 09/808,832

GROUP ART UNIT: 1614

FILED: MARCH 15, 2001

EXAMINER: UNKNOWN

FOR: PEPTIDE-CLEAVABLE, TARGETED ANTINEOPLASTIC DRUGS AND THEIR THERAPEUTIC USE

I hereby certify that this correspondence, a **Notice to File Missing Parts, Fee Transmittal Sheet, Declaration (3 pages), Power of Attorney (10 pages), Marked-Up Copy of Sequence List, Disc, PTO Copy of Notice to File Missing Parts, and Sequence Listing**, are being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to:

Assistant Commissioner for Patents
Washington, D.C. 20231

June 26, 2001
Date

Diana C. Pickering
Signature

Diana C. Pickering
Type or printed name of person signing Certificate

Note: Each paper must have its own certificate of mailing, or this certificate must identify each submitted paper.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

FREE TRANSMITTAL
for FY 2001

Patent fees are subject to annual revision.

TOTAL AMOUNT OF PAYMENT (\$) 130.00

Complete if Known

Application Number	09/808,832
Filing Date	March 15, 2001
First Named Inventor	Copeland et al
Examiner Name	Unknown
Group / Art Unit	1614
Attorney Docket No.	PH-7134

METHOD OF PAYMENT (check one)		FEE CALCULATION (continued)																																																																																																																																																																															
<p>1. <input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge indicated fees and credit any over payments to:</p> <p>Deposit Account Number: 04-1928</p> <p>Deposit Account Name: DuPont Pharmaceuticals Company</p> <p><input checked="" type="checkbox"/> Charge Any Additional Fee Required Under 37 CFR 1.16 and 1.17</p> <p><input type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27</p> <p>2. <input type="checkbox"/> Payment Enclosed:</p> <p><input type="checkbox"/> Check <input type="checkbox"/> Credit card <input type="checkbox"/> Money Order <input type="checkbox"/> Other</p>		<p>3. ADDITIONAL FEES</p> <table border="1"> <thead> <tr> <th>Large Fee Code</th> <th>Entity Fee (\$)</th> <th>Small Fee Code</th> <th>Entity Fee (\$)</th> <th>Fee Description</th> <th>Fee Paid</th> </tr> </thead> <tbody> <tr> <td>105</td> <td>130</td> <td>205</td> <td>65</td> <td>Surcharge - late filing fee or oath</td> <td>130</td> </tr> <tr> <td>127</td> <td>50</td> <td>227</td> <td>25</td> <td>Surcharge - late provisional filing fee or cover sheet.</td> <td></td> </tr> <tr> <td>139</td> <td>130</td> <td>139</td> <td>130</td> <td>Non-English specification</td> <td></td> </tr> <tr> <td>147</td> <td>2,520</td> <td>147</td> <td>2,520</td> <td>For filing a request for ex parte reexamination</td> <td></td> </tr> <tr> <td>112</td> <td>920*</td> <td>112</td> <td>920*</td> <td>Requesting publication of SIR prior to Examiner action</td> <td></td> </tr> <tr> <td>113</td> <td>1,840*</td> <td>113</td> <td>1,840*</td> <td>Requesting publication of SIR after Examiner action</td> <td></td> </tr> <tr> <td>115</td> <td>110</td> <td>215</td> <td>55</td> <td>Extension for reply within first month</td> <td></td> </tr> <tr> <td>116</td> <td>390</td> <td>216</td> <td>195</td> <td>Extension for reply within second month</td> <td></td> </tr> <tr> <td>117</td> <td>890</td> <td>217</td> <td>445</td> <td>Extension for reply within third month</td> <td></td> </tr> <tr> <td>118</td> <td>1,390</td> <td>218</td> <td>695</td> <td>Extension for reply within fourth month</td> <td></td> </tr> <tr> <td>128</td> <td>1,890</td> <td>228</td> <td>945</td> <td>Extension for reply within fifth month</td> <td></td> </tr> <tr> <td>119</td> <td>310</td> <td>219</td> <td>155</td> <td>Notice of Appeal</td> <td></td> </tr> <tr> <td>120</td> <td>310</td> <td>220</td> <td>155</td> <td>Filing a brief in support of an appeal</td> <td></td> </tr> <tr> <td>121</td> <td>270</td> <td>221</td> <td>135</td> <td>Request for oral hearing</td> <td></td> </tr> <tr> <td>138</td> <td>1,510</td> <td>138</td> <td>1,510</td> <td>Petition to institute a public use proceeding</td> <td></td> </tr> <tr> <td>140</td> <td>110</td> <td>240</td> <td>55</td> <td>Petition to revive - unavoidable</td> <td></td> </tr> <tr> <td>141</td> <td>1,240</td> <td>241</td> <td>620</td> <td>Petition to revive - unintentional</td> <td></td> </tr> <tr> <td>142</td> <td>1,240</td> <td>242</td> <td>620</td> <td>Utility issue fee (or reissue)</td> <td></td> </tr> <tr> <td>143</td> <td>440</td> <td>243</td> <td>220</td> <td>Design issue fee</td> <td></td> </tr> <tr> <td>144</td> <td>600</td> <td>244</td> <td>300</td> <td>Plant issue fee</td> <td></td> </tr> <tr> <td>122</td> <td>130</td> <td>122</td> <td>130</td> <td>Petitions to the Commissioner</td> <td></td> </tr> <tr> <td>123</td> <td>130</td> <td>123</td> <td>50</td> <td>Petitions related to provisional applications</td> <td></td> </tr> <tr> <td>126</td> <td>240</td> <td>126</td> <td>240</td> <td>Submission of Information Disclosure Stmt</td> <td></td> </tr> <tr> <td>581</td> <td>40</td> <td>581</td> <td>40</td> <td>Recording each patent assignment per property (times number of properties)</td> <td></td> </tr> <tr> <td>146</td> <td>710</td> <td>246</td> <td>355</td> <td>Filing a submission after final rejection (37 CFR § 1.129(a))</td> <td></td> </tr> <tr> <td>149</td> <td>710</td> <td>249</td> <td>355</td> <td>For each additional invention to be examined (37 CFR § 1.129(b))</td> <td></td> </tr> <tr> <td>179 (RCE)</td> <td>710</td> <td>279</td> <td>355</td> <td>Request for Continued Examination</td> <td></td> </tr> <tr> <td>169</td> <td>900</td> <td>169</td> <td>900</td> <td>Request for expedited examination of a design application</td> <td></td> </tr> </tbody> </table> <p>Other fee (specify) _____</p> <p>*Reduced by Basic Filing Fee Paid</p> <p>SUBTOTAL (3) (\$) 130.00</p>		Large Fee Code	Entity Fee (\$)	Small Fee Code	Entity Fee (\$)	Fee Description	Fee Paid	105	130	205	65	Surcharge - late filing fee or oath	130	127	50	227	25	Surcharge - late provisional filing fee or cover sheet.		139	130	139	130	Non-English specification		147	2,520	147	2,520	For filing a request for ex parte reexamination		112	920*	112	920*	Requesting publication of SIR prior to Examiner action		113	1,840*	113	1,840*	Requesting publication of SIR after Examiner action		115	110	215	55	Extension for reply within first month		116	390	216	195	Extension for reply within second month		117	890	217	445	Extension for reply within third month		118	1,390	218	695	Extension for reply within fourth month		128	1,890	228	945	Extension for reply within fifth month		119	310	219	155	Notice of Appeal		120	310	220	155	Filing a brief in support of an appeal		121	270	221	135	Request for oral hearing		138	1,510	138	1,510	Petition to institute a public use proceeding		140	110	240	55	Petition to revive - unavoidable		141	1,240	241	620	Petition to revive - unintentional		142	1,240	242	620	Utility issue fee (or reissue)		143	440	243	220	Design issue fee		144	600	244	300	Plant issue fee		122	130	122	130	Petitions to the Commissioner		123	130	123	50	Petitions related to provisional applications		126	240	126	240	Submission of Information Disclosure Stmt		581	40	581	40	Recording each patent assignment per property (times number of properties)		146	710	246	355	Filing a submission after final rejection (37 CFR § 1.129(a))		149	710	249	355	For each additional invention to be examined (37 CFR § 1.129(b))		179 (RCE)	710	279	355	Request for Continued Examination		169	900	169	900	Request for expedited examination of a design application	
Large Fee Code	Entity Fee (\$)	Small Fee Code	Entity Fee (\$)	Fee Description	Fee Paid																																																																																																																																																																												
105	130	205	65	Surcharge - late filing fee or oath	130																																																																																																																																																																												
127	50	227	25	Surcharge - late provisional filing fee or cover sheet.																																																																																																																																																																													
139	130	139	130	Non-English specification																																																																																																																																																																													
147	2,520	147	2,520	For filing a request for ex parte reexamination																																																																																																																																																																													
112	920*	112	920*	Requesting publication of SIR prior to Examiner action																																																																																																																																																																													
113	1,840*	113	1,840*	Requesting publication of SIR after Examiner action																																																																																																																																																																													
115	110	215	55	Extension for reply within first month																																																																																																																																																																													
116	390	216	195	Extension for reply within second month																																																																																																																																																																													
117	890	217	445	Extension for reply within third month																																																																																																																																																																													
118	1,390	218	695	Extension for reply within fourth month																																																																																																																																																																													
128	1,890	228	945	Extension for reply within fifth month																																																																																																																																																																													
119	310	219	155	Notice of Appeal																																																																																																																																																																													
120	310	220	155	Filing a brief in support of an appeal																																																																																																																																																																													
121	270	221	135	Request for oral hearing																																																																																																																																																																													
138	1,510	138	1,510	Petition to institute a public use proceeding																																																																																																																																																																													
140	110	240	55	Petition to revive - unavoidable																																																																																																																																																																													
141	1,240	241	620	Petition to revive - unintentional																																																																																																																																																																													
142	1,240	242	620	Utility issue fee (or reissue)																																																																																																																																																																													
143	440	243	220	Design issue fee																																																																																																																																																																													
144	600	244	300	Plant issue fee																																																																																																																																																																													
122	130	122	130	Petitions to the Commissioner																																																																																																																																																																													
123	130	123	50	Petitions related to provisional applications																																																																																																																																																																													
126	240	126	240	Submission of Information Disclosure Stmt																																																																																																																																																																													
581	40	581	40	Recording each patent assignment per property (times number of properties)																																																																																																																																																																													
146	710	246	355	Filing a submission after final rejection (37 CFR § 1.129(a))																																																																																																																																																																													
149	710	249	355	For each additional invention to be examined (37 CFR § 1.129(b))																																																																																																																																																																													
179 (RCE)	710	279	355	Request for Continued Examination																																																																																																																																																																													
169	900	169	900	Request for expedited examination of a design application																																																																																																																																																																													
<p>FEE CALCULATION</p> <p>1. BASIC FILING FEE</p> <table border="1"> <thead> <tr> <th>Large Fee Code</th> <th>Entity Fee (\$)</th> <th>Small Fee Code</th> <th>Entity Fee (\$)</th> <th>Fee Description</th> <th>Fee Paid</th> </tr> </thead> <tbody> <tr> <td>101</td> <td>710</td> <td>201</td> <td>355</td> <td>Utility filing fee</td> <td></td> </tr> <tr> <td>106</td> <td>320</td> <td>206</td> <td>160</td> <td>Design filing fee</td> <td></td> </tr> <tr> <td>107</td> <td>490</td> <td>207</td> <td>245</td> <td>Plant filing fee</td> <td></td> </tr> <tr> <td>108</td> <td>710</td> <td>208</td> <td>355</td> <td>Reissue filing fee</td> <td></td> </tr> <tr> <td>114</td> <td>150</td> <td>214</td> <td>75</td> <td>Provisional filing fee</td> <td></td> </tr> </tbody> </table> <p>SUBTOTAL (1) (\$) _____</p> <p>2. EXTRA CLAIM FEES</p> <table border="1"> <thead> <tr> <th>Total Claims</th> <th>Extra Claims</th> <th>Fee from below</th> <th>Fee Paid</th> </tr> </thead> <tbody> <tr> <td>Independent Claims</td> <td>-20** = 0</td> <td>X</td> <td>= 0</td> </tr> <tr> <td>Multiple Dependent</td> <td>-3** = 0</td> <td>X</td> <td>= 0</td> </tr> </tbody> </table> <table border="1"> <thead> <tr> <th>Large Fee Code</th> <th>Entity Fee (\$)</th> <th>Small Fee Code</th> <th>Entity Fee (\$)</th> <th>Fee Description</th> <th>Fee Paid</th> </tr> </thead> <tbody> <tr> <td>103</td> <td>18</td> <td>203</td> <td>9</td> <td>Claims in excess of 20</td> <td></td> </tr> <tr> <td>102</td> <td>80</td> <td>202</td> <td>40</td> <td>Independent claims in excess of 3</td> <td></td> </tr> <tr> <td>104</td> <td>270</td> <td>204</td> <td>135</td> <td>Multiple dependent claim, if not paid</td> <td></td> </tr> <tr> <td>109</td> <td>80</td> <td>209</td> <td>40</td> <td>** Reissue independent claims over original patent</td> <td></td> </tr> <tr> <td>110</td> <td>18</td> <td>210</td> <td>9</td> <td>** Reissue claims in excess of 20 and over original patent</td> <td></td> </tr> </tbody> </table> <p>SUBTOTAL (2) (\$) _____</p> <p>**or number previously paid, if greater; For Reissues, see above</p>		Large Fee Code	Entity Fee (\$)	Small Fee Code	Entity Fee (\$)	Fee Description	Fee Paid	101	710	201	355	Utility filing fee		106	320	206	160	Design filing fee		107	490	207	245	Plant filing fee		108	710	208	355	Reissue filing fee		114	150	214	75	Provisional filing fee		Total Claims	Extra Claims	Fee from below	Fee Paid	Independent Claims	-20** = 0	X	= 0	Multiple Dependent	-3** = 0	X	= 0	Large Fee Code	Entity Fee (\$)	Small Fee Code	Entity Fee (\$)	Fee Description	Fee Paid	103	18	203	9	Claims in excess of 20		102	80	202	40	Independent claims in excess of 3		104	270	204	135	Multiple dependent claim, if not paid		109	80	209	40	** Reissue independent claims over original patent		110	18	210	9	** Reissue claims in excess of 20 and over original patent																																																																																													
Large Fee Code	Entity Fee (\$)	Small Fee Code	Entity Fee (\$)	Fee Description	Fee Paid																																																																																																																																																																												
101	710	201	355	Utility filing fee																																																																																																																																																																													
106	320	206	160	Design filing fee																																																																																																																																																																													
107	490	207	245	Plant filing fee																																																																																																																																																																													
108	710	208	355	Reissue filing fee																																																																																																																																																																													
114	150	214	75	Provisional filing fee																																																																																																																																																																													
Total Claims	Extra Claims	Fee from below	Fee Paid																																																																																																																																																																														
Independent Claims	-20** = 0	X	= 0																																																																																																																																																																														
Multiple Dependent	-3** = 0	X	= 0																																																																																																																																																																														
Large Fee Code	Entity Fee (\$)	Small Fee Code	Entity Fee (\$)	Fee Description	Fee Paid																																																																																																																																																																												
103	18	203	9	Claims in excess of 20																																																																																																																																																																													
102	80	202	40	Independent claims in excess of 3																																																																																																																																																																													
104	270	204	135	Multiple dependent claim, if not paid																																																																																																																																																																													
109	80	209	40	** Reissue independent claims over original patent																																																																																																																																																																													
110	18	210	9	** Reissue claims in excess of 20 and over original patent																																																																																																																																																																													

SUBMITTED BY		Complete (if applicable)			
Name (Print/Type)	Kalim S. Fuzail	Registration No. Attorney/Agent	45,805	Telephone	302-992-3215
Signature		Date	6-26-01		

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

RAW SEQUENCE LISTING ERROR REPORT

BIOTECHNOLOGY
SYSTEMS
BRANCH



04/001
06/15/2001



The Biotechnology Systems Branch of the Scientific and Technical Information Center (STIC) detected errors when processing the following computer readable form:

Application Serial Number: 09/808,832

Source: OIPE

Date Processed by STIC: 3/30/2001

THE ATTACHED PRINTOUT EXPLAINS DETECTED ERRORS.

PLEASE FORWARD THIS INFORMATION TO THE APPLICANT BY EITHER:

- 1) INCLUDING A COPY OF THIS PRINTOUT IN YOUR NEXT COMMUNICATION TO THE APPLICANT, WITH A NOTICE TO COMPLY or,
- 2) TELEPHONING APPLICANT AND FAXING A COPY OF THIS PRINTOUT, WITH A NOTICE TO COMPLY

FOR CRF SUBMISSION QUESTIONS, PLEASE CONTACT MARK SPENCER, 703-308-4212.

FOR SEQUENCE RULES INTERPRETATION, PLEASE CONTACT ROBERT WAX, 703-308-4216.

PATENTIN 2.1 e-mail help: patin21help@uspto.gov or phone 703-306-4119 (R. Wax)

PATENTIN 3.0 e-mail help: patin3help@uspto.gov or phone 703-306-4119 (R. Wax)

TO REDUCE ERRORED SEQUENCE LISTINGS, PLEASE USE THE CHECKER VERSION 3.0 PROGRAM, ACCESSIBLE THROUGH THE U.S. PATENT AND TRADEMARK OFFICE WEBSITE. SEE BELOW:

Checker Version 3.0

The Checker Version 3.0 application is a state-of-the-art Windows based software program employing a logical and intuitive user-interface to check whether a sequence listing is in compliance with format and content rules. Checker Version 3.0 works for sequence listings generated for the original version of 37 CFR §§1.821 - 1.825 effective October 1, 1990 (old rules) and the revised version (new rules) effective July 1, 1998 as well as World Intellectual Property Organization (WIPO) Standard ST 25.

Checker Version 3.0 replaces the previous DOS-based version of Checker, and is Y2K compliant. Checker allows public users to check sequence listings in Computer Readable form (CRF) before submitting them to the United States Patent and Trademark Office (USPTO). Use of Checker prior to filing the sequence listing is expected to result in fewer errored sequence listings, thus saving time and money.

Checker Version 3.0 can be downloaded from the USPTO website at the following address:



Raw Sequence Listing Error Summary

ERROR DETECTED SUGGESTED CORRECTION

SERIAL NUMBER: 09/808,832

ATTN: NEW RULES CASES: PLEASE DISREGARD ENGLISH "ALPHA" HEADERS, WHICH WERE INSERTED BY PTO SOFTWARE

- 1 Wrapped Nucleics The number/text at the end of each line "wrapped" down to the next line.
This may occur if your file was retrieved in a word processor after creating it.
Please adjust your right margin to .3, as this will prevent "wrapping".
- 2 Wrapped Aminos The amino acid number/text at the end of each line "wrapped" down to the next line.
This may occur if your file was retrieved in a word processor after creating it.
Please adjust your right margin to .3, as this will prevent "wrapping".
- 3 Incorrect Line Length The rules require that a line not exceed 72 characters in length. This includes spaces.
- 4 Misaligned Amino Acid The numbering under each 5th amino acid is misaligned. This may be caused by the use of tabs
Numbering between the numbering. It is recommended to delete any tabs and use spacing between the numbers.
- 5 Non-ASCII This file was not saved in ASCII (DOS) text, as required by the Sequence Rules.
Please ensure your subsequent submission is saved in ASCII text so that it can be processed.
- 5 Variable Length Sequence(s) contain n's or Xaa's which represented more than one residue.
As per the rules, each n or Xaa can only represent a single residue.
Please present the maximum number of each residue having variable length and
indicate in the (ix) feature section that some may be missing.
- 7 PatentIn ver. 2.0 "bug" A "bug" in PatentIn version 2.0 has caused the <220>-<223> section to be missing from amino acid
sequence(s) . Normally, PatentIn would automatically generate this section from the
previously coded nucleic acid sequence. Please manually copy the relevant <220>-<223> section
to the subsequent amino acid sequence. This applies primarily to the mandatory <220>-<223>
sections for Artificial or Unknown sequences.
- 8 Skipped Sequences Sequence(s) missing. If intentional, please use the following format for each skipped sequence:
(OLD RULES) (2) INFORMATION FOR SEQ ID NO:X:
(i) SEQUENCE CHARACTERISTICS:(Do not insert any headings under "SEQUENCE CHARACTERISTICS")
(xi) SEQUENCE DESCRIPTION:SEQ ID NO:X:
This sequence is intentionally skipped

Please also adjust the "(iii) NUMBER OF SEQUENCES:" response to include the skipped sequence(s).
- 9 Skipped Sequences Sequence(s) missing. If intentional, please use the following format for each skipped sequence.
(NEW RULES) <210> sequence id number
<400> sequence id number
000
- 10 Use of n's or Xaa's Use of n's and/or Xaa's have been detected in the Sequence Listing.
(NEW RULES) Use of <220> to <223> is MANDATORY if n's or Xaa's are present.
In <220> to <223> section, please explain location of n or Xaa, and which residue n or Xaa represents.
- 11 Use of <213>Organism Sequence(s) are missing this mandatory field or its response.
(NEW RULES)
- 12 Use of <220>Feature Sequence(s) are missing the <220>Feature and associated headings.
(NEW RULES) Use of <220> to <223> is MANDATORY if <213>ORGANISM is "Artificial Sequence" or "Unknown"
Please explain source of genetic material in <220> to <223> section.
(See "Federal Register," 6/01/98, Vol. 63, No. 104, pp. 29631-32) (Sec. 1.823 of new Rules)
- 13 PatentIn ver. 2.0 "bug" Please do not use "Copy to Disk" function of PatentIn version 2.0. This causes a corrupted
file, resulting in missing mandatory numeric identifiers and responses (as indicated on raw sequence listing).
Instead, please use "File Manager" or any other means to copy file to floppy disk.



OIPE

RAW SEQUENCE LISTING
PATENT APPLICATION: US/09/808,832

DATE: 03/30/2001
TIME: 15:15:26

Input Set : A:\PTO.txt
Output Set: N:\CRF3\03302001\I808832.raw

Does Not Comply
Corrected Diskette Needed

3 <110> APPLICANT: DuPont Pharmaceuticals Company
5 <120> TITLE OF INVENTION: Peptidase-cleavable, targeted antineoplastic drugs and their therapeutic

6 use

8 <130> FILE REFERENCE: PH-7134

C--> 10 <140> CURRENT APPLICATION NUMBER: US/09/808,832

C--> 10 <141> CURRENT FILING DATE: 2001-03-15

10 <150> PRIOR APPLICATION NUMBER: 60/189,387

11 <151> PRIOR FILING DATE: 2000-03-15

13 <160> NUMBER OF SEQ ID NOS: 210

15 <170> SOFTWARE: PatentIn version 3.0

17 <210> SEQ ID NO: 1

18 <211> LENGTH: 5

19 <212> TYPE: PRT

20 <213> ORGANISM: Artificial

22 <220> FEATURE:

23 <223> OTHER INFORMATION: no comment

25 <220> FEATURE:

26 <221> NAME/KEY: MOD_RES

27 <222> LOCATION: (1)..(1)

28 <223> OTHER INFORMATION: 4-methoxy-benzenesulfonyl-beta-alanine

31 <220> FEATURE:

32 <221> NAME/KEY: MOD_RES

33 <222> LOCATION: (3)..(3)

34 <223> OTHER INFORMATION: homophenylalanine

37 <400> SEQUENCE: 1

39 Xaa Gly Xaa Tyr Leu

40 1 5

42 <210> SEQ ID NO: 2

43 <211> LENGTH: 5

44 <212> TYPE: PRT

45 <213> ORGANISM: Artificial

47 <220> FEATURE:

48 <223> OTHER INFORMATION: no comment

50 <220> FEATURE:

51 <221> NAME/KEY: MOD_RES

52 <222> LOCATION: (1)..(1)

53 <223> OTHER INFORMATION: 1,2-C6H4(CO)2-histidine

56 <220> FEATURE:

57 <221> NAME/KEY: MOD_RES

58 <222> LOCATION: (3)..(3)

59 <223> OTHER INFORMATION: homophenylalanine

62 <400> SEQUENCE: 2

64 Xaa Gly Xaa Tyr Leu

65 1 5

67 <210> SEQ ID NO: 3

68 <211> LENGTH: 5

69 <212> TYPE: PRT

per 1.823 of Sequence Rules, valid response is Artificial Sequence
give source of genetic material - see item 12 on Error summary sheet

RAW SEQUENCE LISTING
PATENT APPLICATION: US/09/808,832

DATE: 03/30/2001
TIME: 15:15:26

Input Set : A:\PTO.txt
Output Set: N:\CRF3\03302001\I808832.raw

70 <213> ORGANISM: Artificial
72 <220> FEATURE:
73 <223> OTHER INFORMATION: no comment
75 <220> FEATURE:
76 <221> NAME/KEY: MOD_RES
77 <222> LOCATION: (1)..(1)
78 <223> OTHER INFORMATION: acetyl-proline
81 <400> SEQUENCE: 3
OK 83 Xaa Leu Gly Leu Leu
84 1 5
86 <210> SEQ ID NO: 4
87 <211> LENGTH: 5
88 <212> TYPE: PRT
89 <213> ORGANISM: Artificial
91 <220> FEATURE:
92 <223> OTHER INFORMATION: no comment
94 <220> FEATURE:
95 <221> NAME/KEY: MOD_RES
96 <222> LOCATION: (1)..(1)
97 <223> OTHER INFORMATION: acetyl-proline
100 <400> SEQUENCE: 4
OK 102 Xaa Leu Gly Leu Leu
103 1 5
105 <210> SEQ ID NO: 5
106 <211> LENGTH: 5
107 <212> TYPE: PRT
108 <213> ORGANISM: Artificial
110 <220> FEATURE:
111 <223> OTHER INFORMATION: no comment
113 <220> FEATURE:
114 <221> NAME/KEY: MOD_RES
115 <222> LOCATION: (2)..(2)
116 <223> OTHER INFORMATION: beta alanine
119 <220> FEATURE:
120 <221> NAME/KEY: MOD_RES
121 <222> LOCATION: (1)..(1)
122 <223> OTHER INFORMATION: acetyl-proline
125 <400> SEQUENCE: 5
OK 127 Xaa Xaa Gly Leu Leu
128 1 5
130 <210> SEQ ID NO: 6
131 <211> LENGTH: 5
132 <212> TYPE: PRT
133 <213> ORGANISM: Artificial
135 <220> FEATURE:
136 <223> OTHER INFORMATION: no comment
138 <220> FEATURE:
139 <221> NAME/KEY: MOD_RES
140 <222> LOCATION: (2)..(2)

RAW SEQUENCE LISTING
PATENT APPLICATION: US/09/808,832

DATE: 03/30/2001
TIME: 15:15:26

Input Set : A:\PTO.txt
Output Set: N:\CRF3\03302001\I808832.raw

141 <223> OTHER INFORMATION: 4-aminobutyric acid

144 <220> FEATURE:

145 <221> NAME/KEY: MOD_RES

146 <222> LOCATION: (1)..(1)

147 <223> OTHER INFORMATION: acetyl-proline

150 <400> SEQUENCE: 6

152 Xaa Xaa Gly Leu Leu

153 1 5

155 <210> SEQ ID NO: 7

156 <211> LENGTH: 5

157 <212> TYPE: PRT

158 <213> ORGANISM: Artificial

160 <220> FEATURE:

161 <223> OTHER INFORMATION: no comment

163 <220> FEATURE:

164 <221> NAME/KEY: MOD_RES

165 <222> LOCATION: (2)..(2)

166 <223> OTHER INFORMATION: cyclohexylalanine

169 <220> FEATURE:

170 <221> NAME/KEY: MOD_RES

171 <222> LOCATION: (1)..(1)

172 <223> OTHER INFORMATION: acetyl-proline

175 <400> SEQUENCE: 7

177 Xaa Xaa Gly Leu Leu

178 1 5

180 <210> SEQ ID NO: 8

181 <211> LENGTH: 5

182 <212> TYPE: PRT

183 <213> ORGANISM: Artificial

185 <220> FEATURE:

186 <223> OTHER INFORMATION: no comment

188 <400> SEQUENCE: 8

190 Pro Leu Gly Leu Leu

191 1 5

193 <210> SEQ ID NO: 9

194 <211> LENGTH: 5

195 <212> TYPE: PRT

196 <213> ORGANISM: Artificial

198 <220> FEATURE:

199 <223> OTHER INFORMATION: no comment

201 <220> FEATURE:

202 <221> NAME/KEY: MOD_RES

203 <222> LOCATION: (1)..(1)

204 <223> OTHER INFORMATION: MeOCH₂CH₂OCH₂(=O)-proline

207 <400> SEQUENCE: 9

209 Xaa Leu Gly Leu Leu

210 1 5

212 <210> SEQ ID NO: 10

213 <211> LENGTH: 5

RAW SEQUENCE LISTING
PATENT APPLICATION: US/09/808,832

DATE: 03/30/2001
TIME: 15:15:26

Input Set : A:\PTO.txt
Output Set: N:\CRF3\03302001\I808832.raw

214 <212> TYPE: PRT
215 <213> ORGANISM: Artificial
217 <220> FEATURE:
218 <223> OTHER INFORMATION: no comment
220 <220> FEATURE:
221 <221> NAME/KEY: MOD_RES
222 <222> LOCATION: (1)..(1)
223 <223> OTHER INFORMATION: MeOCH₂CH₂OCH₂CH₂OCH₂C(=O)-proline
226 <400> SEQUENCE: 10
OK 228 Xaa Leu Gly Leu Leu
229 1 5
231 <210> SEQ ID NO: 11
232 <211> LENGTH: 5
233 <212> TYPE: PRT
234 <213> ORGANISM: Artificial
236 <220> FEATURE:
237 <223> OTHER INFORMATION: no comment
239 <220> FEATURE:
240 <221> NAME/KEY: MOD_RES
241 <222> LOCATION: (1)..(1)
242 <223> OTHER INFORMATION: H₂NCH₂CH₂N(CH₂CH₂)₂NCH₂C(=O)-proline
245 <400> SEQUENCE: 11
OK 247 Xaa Leu Gly Leu Leu
248 1 5
250 <210> SEQ ID NO: 12
251 <211> LENGTH: 5
252 <212> TYPE: PRT
253 <213> ORGANISM: Artificial
255 <220> FEATURE:
256 <223> OTHER INFORMATION: no comment
258 <220> FEATURE:
259 <221> NAME/KEY: MOD_RES
260 <222> LOCATION: (1)..(1)
261 <223> OTHER INFORMATION: AcHNCH₂CH₂N(CH₂CH₂)₂NCH₂C(=O)-proline
264 <400> SEQUENCE: 12
OK 266 Xaa Leu Gly Leu Leu
267 1 5
269 <210> SEQ ID NO: 13
270 <211> LENGTH: 5
271 <212> TYPE: PRT
272 <213> ORGANISM: Artificial
274 <220> FEATURE:
275 <223> OTHER INFORMATION: no comment
277 <220> FEATURE:
278 <221> NAME/KEY: MOD_RES
279 <222> LOCATION: (1)..(1)
280 <223> OTHER INFORMATION: AcN(CH₂CH₂)₂NCH₂C(=O)-proline
283 <400> SEQUENCE: 13
OK 285 Xaa Leu Gly Leu Leu

RAW SEQUENCE LISTING
PATENT APPLICATION: US/09/808,832

DATE: 03/30/2001
TIME: 15:15:26

Input Set : A:\PTO.txt
Output Set: N:\CRF3\03302001\I808832.raw

286 1 5
288 <210> SEQ ID NO: 14
289 <211> LENGTH: 4
290 <212> TYPE: PRT
291 <213> ORGANISM: Artificial
293 <220> FEATURE:
294 <223> OTHER INFORMATION: no comment
296 <220> FEATURE:
297 <221> NAME/KEY: MOD_RES
298 <222> LOCATION: (4)..(4)
299 <223> OTHER INFORMATION: O-benzyl-serine
302 <400> SEQUENCE: 14
OK 304 Pro Leu Gly Xaa
305 1
307 <210> SEQ ID NO: 15
308 <211> LENGTH: 4
309 <212> TYPE: PRT
310 <213> ORGANISM: Artificial
312 <220> FEATURE:
313 <223> OTHER INFORMATION: no comment
315 <220> FEATURE:
316 <221> NAME/KEY: MOD_RES
317 <222> LOCATION: (1)..(1)
318 <223> OTHER INFORMATION: acetyl-proline
321 <400> SEQUENCE: 15
OK 323 Xaa Leu Gly Leu
324 1
326 <210> SEQ ID NO: 16
327 <211> LENGTH: 5
328 <212> TYPE: PRT
329 <213> ORGANISM: Artificial
331 <220> FEATURE:
332 <223> OTHER INFORMATION: no comment
334 <220> FEATURE:
335 <221> NAME/KEY: MOD_RES
336 <222> LOCATION: (1)..(1)
337 <223> OTHER INFORMATION: acetyl-glycine
340 <400> SEQUENCE: 16
OK 342 Xaa Pro Leu Gly Leu
343 1 5
345 <210> SEQ ID NO: 17
346 <211> LENGTH: 6
347 <212> TYPE: PRT
348 <213> ORGANISM: Artificial
350 <220> FEATURE:
351 <223> OTHER INFORMATION: no comment
353 <220> FEATURE:
354 <221> NAME/KEY: MOD_RES
355 <222> LOCATION: (1)..(1)

*Please correct these errors
in subsequent sequences
too.*

Please Note:

Use of n and/or Xaa have been detected in the Sequence Listing. Please review the
Sequence Listing to ensure that a corresponding explanation is presented in the <220> to

VERIFICATION SUMMARY
PATENT APPLICATION: US/09/808,832

DATE: 03/30/2001
TIME: 15:15:27

Input Set : A:\PTO.txt
Output Set: N:\CRF3\03302001\I808832.raw

L:10 M:270 C: Current Application Number differs, Replaced Current Application No
L:10 M:271 C: Current Filing Date differs, Replaced Current Filing Date
L:39 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:1
L:64 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:2
L:83 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:3
L:102 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:4
L:127 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:5
L:152 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:6
L:177 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:7
L:209 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:9
L:228 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:10
L:247 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:11
L:266 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:12
L:285 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:13
L:304 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:14
L:323 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:15
L:342 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:16
L:373 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:17
L:398 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:18
L:429 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:19
L:460 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:20
L:491 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:21
L:516 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:22
L:541 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:23
L:566 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:24
L:591 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:25
L:616 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:26
L:641 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:27
L:666 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:28
L:691 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:29
L:710 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:30
L:729 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:31
L:748 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:32
L:773 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:33
L:804 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:34
L:823 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:35
L:842 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:36
L:861 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:37
L:886 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:38
L:905 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:39
L:924 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:40
L:943 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:41
L:962 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:42
L:981 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:43
L:1000 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:44
L:1019 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:45
L:1038 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:46
L:1057 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:47

VERIFICATION SUMMARY

PATENT APPLICATION: US/09/808,832

DATE: 03/30/2001

TIME: 15:15:27

Input Set : A:\PTO.txt

Output Set: N:\CRF3\03302001\I808832.raw

∴1076 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:48
∴1095 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:49
∴1114 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:50
∴1133 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:51